ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Macular Degeneration Drug Pipeline Market Research Report 2025
Published Date: June 2025
|
Report Code: QYRE-Auto-16N5013
Home | Market Reports | Health| Vision Care
Global Macular Degeneration Drug Pipeline Market Insights Forecast to 2028
BUY CHAPTERS

Global Macular Degeneration Drug Pipeline Market Research Report 2025

Code: QYRE-Auto-16N5013
Report
June 2025
Pages:92
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Amgen Inc
Roche
Adverum Biotechnologies
AsclepiX Therapeutics
Bioeq AG
Sinocelltech Ltd
RemeGen, Ltd.
Grifols S A
Kyowa Kirin
EyePoint Pharmaceutical
IVERIC bio
Kodiak Sciences
Ribomic Inc
Lineage Cell Therapeutics
Graybug Vision
CHABiotech
Shanghai Henlius Biotech
Bio-Thera Solutions
Alteogen
Outlook Therapeutics

Macular Degeneration Drug Pipeline Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Macular Degeneration Drug Pipeline Market

Macular Degeneration Drug Pipeline Market

The global market for Macular Degeneration Drug Pipeline was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Macular Degeneration Drug Pipeline, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Macular Degeneration Drug Pipeline.
The Macular Degeneration Drug Pipeline market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Macular Degeneration Drug Pipeline market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Macular Degeneration Drug Pipeline companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Macular Degeneration Drug Pipeline Market Report

Report Metric Details
Report Name Macular Degeneration Drug Pipeline Market
CAGR 5%
Segment by Type
Segment by Application
  • Hospital
  • Research Institute
  • Commercial
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Amgen, Roche, Adverum Biotechnologies, AsclepiX Therapeutics, Bioeq AG, Sinocelltech, RemeGen, Grifols, S.A., Kyowa Kirin, EyePoint Pharmaceutical, IVERIC Bio, Kodiak Sciences, Ribomic, Lineage Cell Therapeutics, Graybug Vision, CHABiotech, Shanghai Henlius Biotech, Bio-Thera Solutions, Alteogen, Outlook Therapeutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Macular Degeneration Drug Pipeline company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Macular Degeneration Drug Pipeline Market report?

Ans: The main players in the Macular Degeneration Drug Pipeline Market are Amgen, Roche, Adverum Biotechnologies, AsclepiX Therapeutics, Bioeq AG, Sinocelltech, RemeGen, Grifols, S.A., Kyowa Kirin, EyePoint Pharmaceutical, IVERIC Bio, Kodiak Sciences, Ribomic, Lineage Cell Therapeutics, Graybug Vision, CHABiotech, Shanghai Henlius Biotech, Bio-Thera Solutions, Alteogen, Outlook Therapeutics

What are the Application segmentation covered in the Macular Degeneration Drug Pipeline Market report?

Ans: The Applications covered in the Macular Degeneration Drug Pipeline Market report are Hospital, Research Institute, Commercial, Other

What are the Type segmentation covered in the Macular Degeneration Drug Pipeline Market report?

Ans: The Types covered in the Macular Degeneration Drug Pipeline Market report are Gene therapy, Small molecules, Stem cell therapy, Gene therapies

Recommended Reports

Ophthalmology & Eye Treatments

Macular & Retinal Diseases

Neurological & Chronic Disease Drugs

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Gene therapy
1.2.3 Small molecules
1.2.4 Stem cell therapy
1.2.5 Gene therapies
1.3 Market by Application
1.3.1 Global Macular Degeneration Drug Pipeline Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Research Institute
1.3.4 Commercial
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Macular Degeneration Drug Pipeline Market Perspective (2020-2031)
2.2 Global Macular Degeneration Drug Pipeline Growth Trends by Region
2.2.1 Global Macular Degeneration Drug Pipeline Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Macular Degeneration Drug Pipeline Historic Market Size by Region (2020-2025)
2.2.3 Macular Degeneration Drug Pipeline Forecasted Market Size by Region (2026-2031)
2.3 Macular Degeneration Drug Pipeline Market Dynamics
2.3.1 Macular Degeneration Drug Pipeline Industry Trends
2.3.2 Macular Degeneration Drug Pipeline Market Drivers
2.3.3 Macular Degeneration Drug Pipeline Market Challenges
2.3.4 Macular Degeneration Drug Pipeline Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue
3.1.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue (2020-2025)
3.1.2 Global Macular Degeneration Drug Pipeline Revenue Market Share by Players (2020-2025)
3.2 Global Macular Degeneration Drug Pipeline Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Macular Degeneration Drug Pipeline Revenue
3.4 Global Macular Degeneration Drug Pipeline Market Concentration Ratio
3.4.1 Global Macular Degeneration Drug Pipeline Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration Drug Pipeline Revenue in 2024
3.5 Global Key Players of Macular Degeneration Drug Pipeline Head office and Area Served
3.6 Global Key Players of Macular Degeneration Drug Pipeline, Product and Application
3.7 Global Key Players of Macular Degeneration Drug Pipeline, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Macular Degeneration Drug Pipeline Breakdown Data by Type
4.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Type (2020-2025)
4.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Type (2026-2031)
5 Macular Degeneration Drug Pipeline Breakdown Data by Application
5.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Application (2020-2025)
5.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Macular Degeneration Drug Pipeline Market Size (2020-2031)
6.2 North America Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Macular Degeneration Drug Pipeline Market Size by Country (2020-2025)
6.4 North America Macular Degeneration Drug Pipeline Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Macular Degeneration Drug Pipeline Market Size (2020-2031)
7.2 Europe Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Macular Degeneration Drug Pipeline Market Size by Country (2020-2025)
7.4 Europe Macular Degeneration Drug Pipeline Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size (2020-2031)
8.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2020-2025)
8.4 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Macular Degeneration Drug Pipeline Market Size (2020-2031)
9.2 Latin America Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2020-2025)
9.4 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size (2020-2031)
10.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2020-2025)
10.4 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Macular Degeneration Drug Pipeline Introduction
11.1.4 Amgen Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.1.5 Amgen Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Macular Degeneration Drug Pipeline Introduction
11.2.4 Roche Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.2.5 Roche Recent Development
11.3 Adverum Biotechnologies
11.3.1 Adverum Biotechnologies Company Details
11.3.2 Adverum Biotechnologies Business Overview
11.3.3 Adverum Biotechnologies Macular Degeneration Drug Pipeline Introduction
11.3.4 Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.3.5 Adverum Biotechnologies Recent Development
11.4 AsclepiX Therapeutics
11.4.1 AsclepiX Therapeutics Company Details
11.4.2 AsclepiX Therapeutics Business Overview
11.4.3 AsclepiX Therapeutics Macular Degeneration Drug Pipeline Introduction
11.4.4 AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.4.5 AsclepiX Therapeutics Recent Development
11.5 Bioeq AG
11.5.1 Bioeq AG Company Details
11.5.2 Bioeq AG Business Overview
11.5.3 Bioeq AG Macular Degeneration Drug Pipeline Introduction
11.5.4 Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.5.5 Bioeq AG Recent Development
11.6 Sinocelltech
11.6.1 Sinocelltech Company Details
11.6.2 Sinocelltech Business Overview
11.6.3 Sinocelltech Macular Degeneration Drug Pipeline Introduction
11.6.4 Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.6.5 Sinocelltech Recent Development
11.7 RemeGen
11.7.1 RemeGen Company Details
11.7.2 RemeGen Business Overview
11.7.3 RemeGen Macular Degeneration Drug Pipeline Introduction
11.7.4 RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.7.5 RemeGen Recent Development
11.8 Grifols, S.A.
11.8.1 Grifols, S.A. Company Details
11.8.2 Grifols, S.A. Business Overview
11.8.3 Grifols, S.A. Macular Degeneration Drug Pipeline Introduction
11.8.4 Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.8.5 Grifols, S.A. Recent Development
11.9 Kyowa Kirin
11.9.1 Kyowa Kirin Company Details
11.9.2 Kyowa Kirin Business Overview
11.9.3 Kyowa Kirin Macular Degeneration Drug Pipeline Introduction
11.9.4 Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.9.5 Kyowa Kirin Recent Development
11.10 EyePoint Pharmaceutical
11.10.1 EyePoint Pharmaceutical Company Details
11.10.2 EyePoint Pharmaceutical Business Overview
11.10.3 EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Introduction
11.10.4 EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.10.5 EyePoint Pharmaceutical Recent Development
11.11 IVERIC Bio
11.11.1 IVERIC Bio Company Details
11.11.2 IVERIC Bio Business Overview
11.11.3 IVERIC Bio Macular Degeneration Drug Pipeline Introduction
11.11.4 IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.11.5 IVERIC Bio Recent Development
11.12 Kodiak Sciences
11.12.1 Kodiak Sciences Company Details
11.12.2 Kodiak Sciences Business Overview
11.12.3 Kodiak Sciences Macular Degeneration Drug Pipeline Introduction
11.12.4 Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.12.5 Kodiak Sciences Recent Development
11.13 Ribomic
11.13.1 Ribomic Company Details
11.13.2 Ribomic Business Overview
11.13.3 Ribomic Macular Degeneration Drug Pipeline Introduction
11.13.4 Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.13.5 Ribomic Recent Development
11.14 Lineage Cell Therapeutics
11.14.1 Lineage Cell Therapeutics Company Details
11.14.2 Lineage Cell Therapeutics Business Overview
11.14.3 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Introduction
11.14.4 Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.14.5 Lineage Cell Therapeutics Recent Development
11.15 Graybug Vision
11.15.1 Graybug Vision Company Details
11.15.2 Graybug Vision Business Overview
11.15.3 Graybug Vision Macular Degeneration Drug Pipeline Introduction
11.15.4 Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.15.5 Graybug Vision Recent Development
11.16 CHABiotech
11.16.1 CHABiotech Company Details
11.16.2 CHABiotech Business Overview
11.16.3 CHABiotech Macular Degeneration Drug Pipeline Introduction
11.16.4 CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.16.5 CHABiotech Recent Development
11.17 Shanghai Henlius Biotech
11.17.1 Shanghai Henlius Biotech Company Details
11.17.2 Shanghai Henlius Biotech Business Overview
11.17.3 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Introduction
11.17.4 Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.17.5 Shanghai Henlius Biotech Recent Development
11.18 Bio-Thera Solutions
11.18.1 Bio-Thera Solutions Company Details
11.18.2 Bio-Thera Solutions Business Overview
11.18.3 Bio-Thera Solutions Macular Degeneration Drug Pipeline Introduction
11.18.4 Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.18.5 Bio-Thera Solutions Recent Development
11.19 Alteogen
11.19.1 Alteogen Company Details
11.19.2 Alteogen Business Overview
11.19.3 Alteogen Macular Degeneration Drug Pipeline Introduction
11.19.4 Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.19.5 Alteogen Recent Development
11.20 Outlook Therapeutics
11.20.1 Outlook Therapeutics Company Details
11.20.2 Outlook Therapeutics Business Overview
11.20.3 Outlook Therapeutics Macular Degeneration Drug Pipeline Introduction
11.20.4 Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2020-2025)
11.20.5 Outlook Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Amgen Inc
Roche
Adverum Biotechnologies
AsclepiX Therapeutics
Bioeq AG
Sinocelltech Ltd
RemeGen, Ltd.
Grifols S A
Kyowa Kirin
EyePoint Pharmaceutical
IVERIC bio
Kodiak Sciences
Ribomic Inc
Lineage Cell Therapeutics
Graybug Vision
CHABiotech
Shanghai Henlius Biotech
Bio-Thera Solutions
Alteogen
Outlook Therapeutics
List of Tables
 Table 1. Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Gene therapy
 Table 3. Key Players of Small molecules
 Table 4. Key Players of Stem cell therapy
 Table 5. Key Players of Gene therapies
 Table 6. Global Macular Degeneration Drug Pipeline Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Macular Degeneration Drug Pipeline Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Macular Degeneration Drug Pipeline Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Macular Degeneration Drug Pipeline Market Share by Region (2020-2025)
 Table 10. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Macular Degeneration Drug Pipeline Market Share by Region (2026-2031)
 Table 12. Macular Degeneration Drug Pipeline Market Trends
 Table 13. Macular Degeneration Drug Pipeline Market Drivers
 Table 14. Macular Degeneration Drug Pipeline Market Challenges
 Table 15. Macular Degeneration Drug Pipeline Market Restraints
 Table 16. Global Macular Degeneration Drug Pipeline Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Macular Degeneration Drug Pipeline Market Share by Players (2020-2025)
 Table 18. Global Top Macular Degeneration Drug Pipeline Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration Drug Pipeline as of 2024)
 Table 19. Ranking of Global Top Macular Degeneration Drug Pipeline Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Macular Degeneration Drug Pipeline Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Macular Degeneration Drug Pipeline, Headquarters and Area Served
 Table 22. Global Key Players of Macular Degeneration Drug Pipeline, Product and Application
 Table 23. Global Key Players of Macular Degeneration Drug Pipeline, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Macular Degeneration Drug Pipeline Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Macular Degeneration Drug Pipeline Revenue Market Share by Type (2020-2025)
 Table 27. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Macular Degeneration Drug Pipeline Revenue Market Share by Type (2026-2031)
 Table 29. Global Macular Degeneration Drug Pipeline Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Macular Degeneration Drug Pipeline Revenue Market Share by Application (2020-2025)
 Table 31. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Macular Degeneration Drug Pipeline Revenue Market Share by Application (2026-2031)
 Table 33. North America Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Macular Degeneration Drug Pipeline Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Macular Degeneration Drug Pipeline Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Macular Degeneration Drug Pipeline Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Macular Degeneration Drug Pipeline Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Macular Degeneration Drug Pipeline Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Macular Degeneration Drug Pipeline Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Macular Degeneration Drug Pipeline Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Amgen Company Details
 Table 49. Amgen Business Overview
 Table 50. Amgen Macular Degeneration Drug Pipeline Product
 Table 51. Amgen Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 52. Amgen Recent Development
 Table 53. Roche Company Details
 Table 54. Roche Business Overview
 Table 55. Roche Macular Degeneration Drug Pipeline Product
 Table 56. Roche Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 57. Roche Recent Development
 Table 58. Adverum Biotechnologies Company Details
 Table 59. Adverum Biotechnologies Business Overview
 Table 60. Adverum Biotechnologies Macular Degeneration Drug Pipeline Product
 Table 61. Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 62. Adverum Biotechnologies Recent Development
 Table 63. AsclepiX Therapeutics Company Details
 Table 64. AsclepiX Therapeutics Business Overview
 Table 65. AsclepiX Therapeutics Macular Degeneration Drug Pipeline Product
 Table 66. AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 67. AsclepiX Therapeutics Recent Development
 Table 68. Bioeq AG Company Details
 Table 69. Bioeq AG Business Overview
 Table 70. Bioeq AG Macular Degeneration Drug Pipeline Product
 Table 71. Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 72. Bioeq AG Recent Development
 Table 73. Sinocelltech Company Details
 Table 74. Sinocelltech Business Overview
 Table 75. Sinocelltech Macular Degeneration Drug Pipeline Product
 Table 76. Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 77. Sinocelltech Recent Development
 Table 78. RemeGen Company Details
 Table 79. RemeGen Business Overview
 Table 80. RemeGen Macular Degeneration Drug Pipeline Product
 Table 81. RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 82. RemeGen Recent Development
 Table 83. Grifols, S.A. Company Details
 Table 84. Grifols, S.A. Business Overview
 Table 85. Grifols, S.A. Macular Degeneration Drug Pipeline Product
 Table 86. Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 87. Grifols, S.A. Recent Development
 Table 88. Kyowa Kirin Company Details
 Table 89. Kyowa Kirin Business Overview
 Table 90. Kyowa Kirin Macular Degeneration Drug Pipeline Product
 Table 91. Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 92. Kyowa Kirin Recent Development
 Table 93. EyePoint Pharmaceutical Company Details
 Table 94. EyePoint Pharmaceutical Business Overview
 Table 95. EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Product
 Table 96. EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 97. EyePoint Pharmaceutical Recent Development
 Table 98. IVERIC Bio Company Details
 Table 99. IVERIC Bio Business Overview
 Table 100. IVERIC Bio Macular Degeneration Drug Pipeline Product
 Table 101. IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 102. IVERIC Bio Recent Development
 Table 103. Kodiak Sciences Company Details
 Table 104. Kodiak Sciences Business Overview
 Table 105. Kodiak Sciences Macular Degeneration Drug Pipeline Product
 Table 106. Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 107. Kodiak Sciences Recent Development
 Table 108. Ribomic Company Details
 Table 109. Ribomic Business Overview
 Table 110. Ribomic Macular Degeneration Drug Pipeline Product
 Table 111. Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 112. Ribomic Recent Development
 Table 113. Lineage Cell Therapeutics Company Details
 Table 114. Lineage Cell Therapeutics Business Overview
 Table 115. Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Product
 Table 116. Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 117. Lineage Cell Therapeutics Recent Development
 Table 118. Graybug Vision Company Details
 Table 119. Graybug Vision Business Overview
 Table 120. Graybug Vision Macular Degeneration Drug Pipeline Product
 Table 121. Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 122. Graybug Vision Recent Development
 Table 123. CHABiotech Company Details
 Table 124. CHABiotech Business Overview
 Table 125. CHABiotech Macular Degeneration Drug Pipeline Product
 Table 126. CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 127. CHABiotech Recent Development
 Table 128. Shanghai Henlius Biotech Company Details
 Table 129. Shanghai Henlius Biotech Business Overview
 Table 130. Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Product
 Table 131. Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 132. Shanghai Henlius Biotech Recent Development
 Table 133. Bio-Thera Solutions Company Details
 Table 134. Bio-Thera Solutions Business Overview
 Table 135. Bio-Thera Solutions Macular Degeneration Drug Pipeline Product
 Table 136. Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 137. Bio-Thera Solutions Recent Development
 Table 138. Alteogen Company Details
 Table 139. Alteogen Business Overview
 Table 140. Alteogen Macular Degeneration Drug Pipeline Product
 Table 141. Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 142. Alteogen Recent Development
 Table 143. Outlook Therapeutics Company Details
 Table 144. Outlook Therapeutics Business Overview
 Table 145. Outlook Therapeutics Macular Degeneration Drug Pipeline Product
 Table 146. Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2020-2025) & (US$ Million)
 Table 147. Outlook Therapeutics Recent Development
 Table 148. Research Programs/Design for This Report
 Table 149. Key Data Information from Secondary Sources
 Table 150. Key Data Information from Primary Sources
 Table 151. Authors List of This Report


List of Figures
 Figure 1. Macular Degeneration Drug Pipeline Picture
 Figure 2. Global Macular Degeneration Drug Pipeline Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Macular Degeneration Drug Pipeline Market Share by Type: 2024 VS 2031
 Figure 4. Gene therapy Features
 Figure 5. Small molecules Features
 Figure 6. Stem cell therapy Features
 Figure 7. Gene therapies Features
 Figure 8. Global Macular Degeneration Drug Pipeline Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Macular Degeneration Drug Pipeline Market Share by Application: 2024 VS 2031
 Figure 10. Hospital Case Studies
 Figure 11. Research Institute Case Studies
 Figure 12. Commercial Case Studies
 Figure 13. Other Case Studies
 Figure 14. Macular Degeneration Drug Pipeline Report Years Considered
 Figure 15. Global Macular Degeneration Drug Pipeline Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 16. Global Macular Degeneration Drug Pipeline Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Macular Degeneration Drug Pipeline Market Share by Region: 2024 VS 2031
 Figure 18. Global Macular Degeneration Drug Pipeline Market Share by Players in 2024
 Figure 19. Global Top Macular Degeneration Drug Pipeline Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration Drug Pipeline as of 2024)
 Figure 20. The Top 10 and 5 Players Market Share by Macular Degeneration Drug Pipeline Revenue in 2024
 Figure 21. North America Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. North America Macular Degeneration Drug Pipeline Market Share by Country (2020-2031)
 Figure 23. United States Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Canada Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Macular Degeneration Drug Pipeline Market Share by Country (2020-2031)
 Figure 27. Germany Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. France Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. U.K. Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Italy Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Russia Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Nordic Countries Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Macular Degeneration Drug Pipeline Market Share by Region (2020-2031)
 Figure 35. China Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Japan Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. South Korea Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Southeast Asia Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. India Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Australia Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Macular Degeneration Drug Pipeline Market Share by Country (2020-2031)
 Figure 43. Mexico Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Brazil Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Macular Degeneration Drug Pipeline Market Share by Country (2020-2031)
 Figure 47. Turkey Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. UAE Macular Degeneration Drug Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Amgen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 51. Roche Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 52. Adverum Biotechnologies Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 53. AsclepiX Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 54. Bioeq AG Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 55. Sinocelltech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 56. RemeGen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 57. Grifols, S.A. Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 58. Kyowa Kirin Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 59. EyePoint Pharmaceutical Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 60. IVERIC Bio Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 61. Kodiak Sciences Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 62. Ribomic Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 63. Lineage Cell Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 64. Graybug Vision Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 65. CHABiotech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 66. Shanghai Henlius Biotech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 67. Bio-Thera Solutions Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 68. Alteogen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 69. Outlook Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2020-2025)
 Figure 70. Bottom-up and Top-down Approaches for This Report
 Figure 71. Data Triangulation
 Figure 72. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Juvenile Macular Degeneration Treatment Market Research Report 2024
Viral Conjunctivitis Pipeline Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Retinal Disorder Treatment Market Research Report 2024
Retinal Dystrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Retinal Disorder Drug Market Research Report 2024
Ophthalmic Disease Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Ophthalmic Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Blepharitis Pipeline Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Neurodegenerative Diseases Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cardiovascular Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Diabetic Retinopathy Fundus Image assisted Diagnosis Software Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Ophthalmic Pharmaceutical Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Neurodegenerative Disease Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Eye Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Choroid Therapy Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Diabetic Macular Edema Drug Market Research Report 2024
Ophthalmology Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ophthalmology AI assisted Diagnosis Software Market Research Report 2024
Alzheimer Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Eye Drug Market Insights Forecast to 2030

RELATED REPORTS

Global High Acuity Care Service Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5D18285
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global mHealth (Mobile Health) Services Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-18B6151
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Resin Lenses Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-21S7871
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Mobile Medical Imaging Services Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-16Q6154
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions